Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
24.61
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
Next >
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
March 14, 2022
Sentiment was low heading into the study and analysts aren't hopeful for other tests.
Via
Investor's Business Daily
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Recap: Alkermes Q4 Earnings
February 16, 2022
Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 16, 2022
February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.
Via
Benzinga
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
February 17, 2022
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant...
Via
Benzinga
Alkermes's Return On Capital Employed Overview
February 17, 2022
According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%...
Via
Benzinga
56 Biggest Movers From Yesterday
February 17, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...
Via
Benzinga
Why Are Alkermes Shares Trading Higher Today?
February 16, 2022
Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
February 16, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Earnings Preview For Alkermes
February 15, 2022
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia
February 08, 2022
Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022
January 27, 2022
Upgrades
Via
Benzinga
BioCorRx Aims To Help Combat Opioid Crisis With Implantable Naltrexone Drug Candidate BICX104
January 24, 2022
Image provided by BioCorRx of a naltrexone pellet This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be...
Via
Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...
Via
Benzinga
Early Monday Report - More Moves Out Of China
January 09, 2022
Before it even turned Monday in the West, China insurers are feeling the heat.
Via
Talk Markets
Happy New Year - Sunday Edition
January 02, 2022
Starting a new year - we look at tech, pharma and mining stocks and their goings-on.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
December 01, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV
Via
Benzinga
75 Biggest Movers From Yesterday
November 10, 2021
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...
Via
Benzinga
Janssen Partially Terminates Nanoparticle License Agreement With Alkermes
November 09, 2021
Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its...
Via
Benzinga
Why Alkermes Stock Is Sinking Today
November 09, 2021
Johnson & Johnson partly ended two licensing agreements with the company.
Via
The Motley Fool
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
November 01, 2021
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future.
Via
InvestorPlace
10 Biggest Price Target Changes For Thursday
October 28, 2021
Oppenheimer lowered Teladoc Health, Inc. (NYSE:TDOC
Via
Benzinga
Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript
October 27, 2021
ALKS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Cyber Currency
October 26, 2021
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.
Via
Talk Markets
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.